Filana Therapeutics annual revenue
2009
2010
2011
2012
2013
2022
2023
2024
2025
Filana Therapeutics reported $0 in revenue for fiscal 2025.
View full Filana Therapeutics company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2013 | 2013-12-31 | $41.1M | $30.2M | +277.58% |
| 2012 | 2012-12-31 | $10.9M | −$594,000 | −5.17% |
| 2011 | 2011-12-31 | $11.5M | −$5.3M | −31.68% |
| 2010 | 2010-12-31 | $16.8M | −$3.8M | −18.26% |
| 2009 | 2009-12-31 | $20.6M | — | — |
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q4 2013 | 2013-12-31 | $35.2M | $32.8M | +1328.04% |
| Q3 2013 | 2013-09-30 | $2.0M | −$767,000 | −28.15% |
| Q2 2013 | 2013-06-30 | $2.0M | −$765,000 | −28.08% |
| Q1 2013 | 2013-03-31 | $2.0M | −$1.0M | −34.14% |
| Q4 2012 | 2012-12-31 | $2.5M | −$279,000 | −10.16% |
| Q3 2012 | 2012-09-30 | $2.7M | −$24,000 | −0.87% |
| Q2 2012 | 2012-06-30 | $2.7M | −$28,000 | −1.02% |
| Q1 2012 | 2012-03-31 | $3.0M | −$263,000 | −8.13% |
| Q4 2011 | 2011-12-31 | $2.7M | — | — |
| Q3 2011 | 2011-09-30 | $2.7M | −$146,000 | −5.04% |
| Q2 2011 | 2011-06-30 | $2.8M | $96,000 | +3.61% |
| Q1 2011 | 2011-03-31 | $3.2M | — | — |
| Q3 2010 | 2010-09-30 | $2.9M | — | — |
| Q2 2010 | 2010-06-30 | $2.7M | — | — |
Filana Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Filana Therapeutics source filings ↗